Amgen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Amgen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About AMGN

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. 

CEO
Robert A. Bradway
CEORobert A. Bradway
Employees
31,500
Employees31,500
Headquarters
Thousand Oaks, California
HeadquartersThousand Oaks, California
Founded
1980
Founded1980
Employees
31,500
Employees31,500

AMGN Key Statistics

Market cap
229.94B
Market cap229.94B
Price-Earnings ratio
26.05
Price-Earnings ratio26.05
Dividend yield
2.34%
Dividend yield2.34%
Average volume
2.65M
Average volume2.65M
High today
$428.00
High today$428.00
Low today
$420.66
Low today$420.66
Open price
$421.64
Open price$421.64
Volume
2.59M
Volume2.59M
52 Week high
$428.00
52 Week high$428.00
52 Week low
$269.77
52 Week low$269.77

Stock Snapshot

The current Amgen(AMGN) stock price is $425.76, with a market capitalization of 229.94B. The stock trades at a price-to-earnings (P/E) ratio of 26.05 and offers a dividend yield of 2.34%.

On 2026-08-18, Amgen(AMGN) stock traded between a low of $420.66 and a high of $428.00. Shares are currently priced at $425.76, which is +1.2% above the low and -0.5% below the high.

The Amgen(AMGN)'s current trading volume is 2.59M, compared to an average daily volume of 2.65M.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $428.00 at its peak.

During the past year, Amgen(AMGN) stock moved between $269.77 at its lowest and $428.00 at its peak.

AMGN News

TipRanks 6h
TScan Therapeutics Faces Loss of Key Amgen Partnership

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

MarketWatch 7h
Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains - marketwatch.com

...

Amgen Inc. stock underperforms Tuesday when compared to competitors despite daily gains - marketwatch.com
Simply Wall St 10h
The Bull Case For Amgen Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why

Amgen Inc. recently reported second-quarter 2026 results showing revenue of US$10,054 million and net income of US$2,375 million, and issued full-year 2026 guid...

The Bull Case For Amgen Could Change Following Raised 2026 Earnings Guidance And Q2 Beat - Learn Why

Analyst ratings

49%

of 35 ratings
Buy
37.1%
Hold
48.6%
Sell
14.3%

More AMGN News

TipRanks 16h
Amgen price target raised to $400 from $350 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Amgen (AMGN) to $400 from $350 and keeps a Neutral rating on the shares. The revised estimates better captur...

TipRanks 1d
Amgen’s Evolocumab Formulation Study Signals Steady Support for Its Cholesterol Franchise

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

Simply Wall St 3d
Should Income Investors Look At Amgen Inc. Before Its Ex-Dividend?

Readers hoping to buy Amgen Inc. ( ) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date occ...

Should Income Investors Look At Amgen Inc. Before Its Ex-Dividend?
TipRanks 3d
Schwab US Dividend Equity ETF Sees Strong Inflows, Stable Performance

Schwab US Dividend Equity ETF ( $SCHD ) has risen by 0.97% in the past week. It has experienced a 5-day net inflow of $858.07 million. This is due, in part, to...

TipRanks 4d
Amgen, Constellation, Fastly, Keel & Blackstone Shock Wall St.

Insiders have been trading these 5 stocks: ((AMGN)), ((CEG)), ((FSLY)), ((KEEL)) and ((BX)). Here is a breakdown of their recent trades and their value. SVP BD...

Nasdaq 4d
GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)

Key Points Amgen is developing a highly differentiated GLP-1 product. Regeneron has a pair of promising GLP-1 candidates in the pipeline. Both biotechs are p...

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk)
TipRanks 4d
Amgen Targets Autoimmune Hepatitis With New Inebilizumab Trial

Amgen Inc (AMGN) announced an update on their ongoing clinical study. Unlock powerful investing tools with TipRanks Premium to make smarter, more confident inv...

People also own

Based on the portfolios of people who own AMGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.